Long-term follow-up and outcome in patients with recurrent respiratory laryngeal papillomatosis by Rasmussen, Eva Rye et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Long-term follow-up and outcome in patients with recurrent respiratory laryngeal
papillomatosis
Rasmussen, Eva Rye; Schnack, Didde T; Jørkov, Andreas Schjellerup; Raja, Anna Axelsson;






Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Rasmussen, E. R., Schnack, D. T., Jørkov, A. S., Raja, A. A., Olsen, C. H., & Homøe, P. (2017). Long-term
follow-up and outcome in patients with recurrent respiratory laryngeal papillomatosis. Danish Medical Journal,
64(12), [A5424].
Download date: 03. Feb. 2020
Dan Med J 64/12  December 2017 DA N I S H M E D I C A L J O U R N A L   1
ABSTRACT 
INTRODUCTION: Recurrent respiratory papillomatosis is 
characterized by wart-like lesions of the upper airway and  
is most frequently caused by human papillomavirus (HPV). 
The disease has significant impact on quality of life due to 
potential airway obstruction, dysphonia and the need for 
serial surgeries. The main objective of this study was to de-
scribe patient characteristics and long-term follow-up data 
in a Danish cohort with the disease.  
METHODS: The study was a longitudinal retrospective co-
hort-study using data from electronic medical records and a 
pathology database. 
RESULTS: A total of 61 adult and four juvenile patients were 
identified. The male-to-female ratio was 2.4. In the adult 
population, the mean age at onset was 45 years. The me-
dian number of surgeries was four (interquartile range: 2.8). 
The mean follow-up time was 8.7 years (range: 7 days-30 
years). Three cases of malignant transformation were ob-
served. In the juvenile population, the mean age of onset 
was 8.5 years (range: 3-12 years). The mean follow-up time 
was 11.5 years (range: 2-23 years), and the number of sur-
geries per year at risk was one/year. CO2-laser and microde-
brider were the surgical techniques usually employed. 43% 
of histopathologic analyses could detect HPV infection (sub-
type 6 or 11). 
CONCLUSIONS: More males than females suffer from respir-
atory papillomatosis; age of onset was either in childhood 
or in mid-life. Use of CO2-laser or microdebrider was the 
preferred surgical approach in this cohort. 
FUNDING: none.
TRIAL REGISTRATION: not relevant.
Recurrent respiratory papillomatosis (RRP) is mainly a 
benign chronic disease of viral aetiology affecting both 
children and adults. Juvenile-onset RRP (JORRP) is de-
fined as disease before the age of 18 years of age and 
adult-onset (AORRP) as onset of disease at 18 years of 
age or later. The disease is characterized by wart-like  
lesions of the upper airway. The incidence is 0.17 per 
100,000 for JORRP and 0.54 per 100,000 for AORRP [1]. 
RRP has three separate peaks in the distribution of age 
at onset; 7, 35 and 64 years [2]. The incidence of RRP 
has not increased over the past five decades [3].
RRP is most commonly caused by persistent infec-
tion of the respiratory epithelium by low-risk human 
papillomavirus (HPV) of subtypes 6 and 11. The onco-
genic HPV subtype 16 has also been identified in rare 
cases [4]. Dysplastic lesions in RRP occur in 10-55% of 
adult cases [5, 6]. Malignant transformation of RRP neo-
plasms occurs in up to 5% of AORRP, but is more rare in 
JORRP [3, 6]. 
RRP has significant impact on health-related quality 
of life (QoL) due to potential airway obstruction, dys-
phonia and the need for serial surgeries [6, 7]. In devel-
oping countries, up to 90% of paediatric RRP patients 
have an emergency tracheostomy performed [8]. There 
is no curable treatment for RRP, and repeated surgical 
procedures are required to control growth, improve 
voice quality and prevent respiratory obstruction. 
Adjuvant therapies have been used with variable success 
[9]. Studies of the quadrivalent HPV vaccine in the RRP 
population have shown conflicting results [10, 11].
New assessment and treatment modalities are cur-
rently being investigated [12]. The introduction of HPV 
vaccines in adolescents around the world may change 
the incidence and epidemiology of RRP. 
The primary aim of this study was to describe pa-
tient characteristics and long-term follow-up data, fo-
cusing on repetitive surgery in a Danish cohort with RRP. 
The secondary aims were to assess the differences in 
surgical approach in our department and to describe a 
population of RRP patients before the introduction of 
the HPV vaccination in Denmark.
METHODS
Study population and design
The study was a retrospective longitudinal cohort-study 
based on evaluation of medical records and pathology 
archives of RRP patients. Patients were included if they 
had been treated for RRP at the Department of Otorhi-
nolaryngology and Maxillofacial Surgery, Zealand Uni-
versity Hospital between 1 January 2004 and 31 May 
2014. 
The population was divided into two groups based 
on data completeness. Medical records and histopath-
ological analyses were available for patients diagnosed 
at our own department during the study period (Group 
1). Baseline, procedural and histology data for patients 
diagnosed and/or treated elsewhere prior to 2004 and 
subsequently treated at our institution (Group 2) were 
less complete. 
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To identify patients with RRP, medical records and 
pathology archives were reviewed. The International 
Code of Disease version 10 (code DD14.1) neoplasma 
benignum laryngis was used to search the medical re-
cord system. Patients were also retrieved by a search  
in the Danish Systematized Nomenclature of Medicine 
“SNOMED” pathology registry using the diagnoses;  
papilloma, light koilocytotic atypia, squamous cell papil-
loma, invert papilloma, papillomatosis and polyps, HPV 
type 6, HPV type 11, HPV. Searches were combined with 
localization to the larynx. Medical records were re-
viewed to extract clinical data, including age, gender, 
age of disease onset, date of first surgery, total number 
of surgeries and last date of follow-up. For patients diag-
nosed before 2004, onset of disease was defined as the 
first date a histopathologic analysis was performed since 
the real date of diagnosis was not available. 
Only four patients with JORRP were identified. They 
were omitted from the statistical analyses and are de-
scribed as a separate entity.
Ethics
The study was approved by the Danish Health and Medi-
cines Authority and by the Danish Data Protection  
Agency (record number 2015-41-3829) as appropriate.
Statistical analysis
Statistical analysis was performed using SAS version 9.4 
(Cary, NC, USA). Normally distributed data (age, fol-
low-up time) are presented as mean ± standard devi-
ation (SD) or mean (range) and non-normally distributed 
data (number of procedures) as median (interquartile 
range (IQR)). Between-group differences for normally 
distributed variables (i.e. age) were evaluated using the 
unpaired Student’s t-test. For non-normally distributed 
continuous variables, we used the Wilcoxon rank sum 
test. Comparison of categorical variables was done with 
the chi-squared test or Fisher’s exact test, when appro-
priate. Correlation was evaluated using Pearson’s cor-
relation coefficient. A p-value < 0.05 was considered 
stat istically significant. 95% confidence intervals (CI) are 
reported where appropriate. “R” (an open source soft-
ware environment for statistical analysis) was used to 
produce Figure 1.
Trial registration: not relevant. 
RESULTS
Baseline data
A total of 65 patients with RRP were identified: 61 pa-
tients (Group 1: 30 and Group 2: 31 patients) with  
AORRP and four with JORRP (Table 1). Among the adult 
patients, 49% were diagnosed at Zealand University Hos-
pital in the 2004-2014 period (Group 1). The male-to- 
female ratio was 2.4. The mean age at onset for AORRP 
was 45 years (SD: ± 15 years). The follow-up time varied 
considerably between Group 1 (mean = 1.9 years, range: 
7 days-9.5 years) and Group 2 (mean = 15.5 years, 
range: 1 month-30 years). Thus, the number of surgical 
procedures also varied between the groups with a mean 
of two procedures for Group 1 and a mean of eight pro-
cedures for Group 2.
In the overall AORRP group, there was no significant 
gender difference for age of onset. However, in the 
group of patients diagnosed prior to 2004 (Group 2) 
compared with Group 1, men were significantly older 
(mean = 48 ± 16 years) at onset than women (mean = 35 
± 10 years), p = 0.02; 95% CI: 2-24 years. 
TABLE 1
Baseline data for juvenile-
onset recurrent respira-
tory papillomatosis pa-
tients (N = 4).
Age at disease onset, yrs, mean (range) 8.5 (3-12)
Male:female, n 1:3
Total follow-up time, yrs 46
Follow-up time, yrs, mean (range) 11.5 (2-23)
Surgical procedures, n, total, mean [median] 46, 11.5 [6]
Surgical procedures/yrs at riska, n 1
a) Yrs at risk = yrs after diagnosis when a patient is “at risk” of further 
surgery.
FIGURE 1
Risk of recurrence over time in in adult-onset recurrent respiratory papillomatosis patients operated 
with either CO2-laser or microdebrider.
Numbers at risk
Laser 19            0                   0 0
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Surgical data
Reliable data for AORRP localization, surgical technique 
and histopathology were available only for surgical pro-
ced ures in patients belonging to Group 1 (Table 2). 
Therefore, Group 2 was excluded from the analyses  
below.
Surgical technique
All 72 procedures in Group 1 were performed using  
microlaryngoscopy with biopsy under general anaesthe-
sia. Surgical details are summarized in Table 2. CO2-laser 
evaporation was primarily used as surgical technique in 
the study period; but in 2012, the surgical microdebrider 
(Medtronic, Minneapolis, USA) was introduced at our 
department and became popular. One surgery was per-
formed using the coblation (Smith&Nephew, London, 
UK) technique. Figure 1 illustrates number of surgical 
procedures with laser (red) or microdebrider (blue) and 
time to recurrence. 
Localization of primary papillomatous lesion
Single-sided papillomatosis was found in 23 patients 
(76.7%), with a predominance of left-sided disease 
(60.9%). In all, 22 of 30 patients had affection of one or 
both vocal cords (73.3%), whereas supra- and subglottic 
localization (four and two patients respectively) was 
more rare (Table 2). The remaining two patients had 
multifocal disease of the larynx (both with involvement 
of the vocal cords).
Histopathology
Out of the 72 procedures in Group 1, the tissue was sub-
mitted for histology in 54 (75%) procedures (30 pa-
tients); and among these, 21 (39%) specimens were as-
sessed for HPV risk status (Table 2).  
Three patients in Group 1 (10%), all of whom were 
tobacco users, were diagnosed with carcinoma. The first 
patient with malignancy was a 55-year-old male. During 
the first procedure, squamous cell papillomas were 
found. Due to clinical suspicion of malignancy, a second 
procedure was performed and histopathological analysis 
showed verrucous carcinoma. Since the tumour invaded 
a lymph node, it was classified as stage T2N1M0, but the 
node stage was doubtful as it was diagnosed only by 
computed tomography and not seen on prior magnetic 
resonance imaging. The second patient was a 50-year-
old male. Histopathology from the sixth surgery showed 
squamous cell carcinoma. The last patient with malig-
nant transformation was a 36-year-old male who had  
severe dysplasia at the first surgery, and histopathology 
from the second procedure two months later revealed 
squamous cell carcinoma. All three patients were re-
ferred for oncologic treatment and follow-up.  
Long-term follow-up
Overall, AORRP patients (Group 1 and Group 2) were  
followed-up for 8.7 years (range: 7 days-30 years) and  
underwent a median of four (IQR: 2-8) surgical proced-
ures. As expected, a significant correlation was observed 
between follow-up time and number of proced ures (r = 
0.55; p < 0.0001) with an event rate of 1.05 procedures 
per year of follow-up, as shown in Figure 2. No signifi-
cant correlations were observed regarding age or gender 
distribution. Figure 1 shows the correlation between 
time to recurrence and surgical method (laser or micro-
debrider). No difference was noted between the two 
methods. 
Five patients (mean age = 44.6 years, two women 
and three men) underwent more than 30 procedures 
each. Two patients were subsequently vaccinated with 
the quadrivalent HPV vaccine, but no effect on recur-
rence was noted. 
TABLE 2
Localization, surgical technique, histopathology and human papillomavi-






Left side 14 –
Right side   9 –




Supraglottic   4 –
Subglottic   2 –
Multiple sites   2 –
Total 30 –
Surgical techniquea
CO2-laser – 32 (44.4)
Microdebrider – 15 (20.8)
CO2-laser and microdebrider –   1 (1.4)
Coblation –   1 (1.4)
Biopsy only – 25 (34.7)
Total – 72 (100)
Histopathologyb
Benign papillomatosis – 51 (94.4)
Squamous cell carcinoma –   2 (3.7)
Verrucous carcinoma –   1 (1.8)
Total – 54 (100)
HPV statusc
HPV low risk type 6 or 11 –   9 (42.9)
No evidence of HPV –   8 (38.1)
P16 negative –   4 (19.0)
Total – 21 (100)
a) Data available for 72 procedures in 30 patients (Group 1).
b) Data available for 54 surgical procedures.
c) Data available for 21 of 54 histopathological analyses.
 4  DA N I S H M E D I C A L J O U R N A L Dan Med J 64/12  December 2017
Juvenile-onset recurrent respiratory papillomatosis
The group of patients with JORRP consisted of one boy 
and three girls (Table 1): The boy was a three-year-old 
who underwent at least ten surgeries during a 12-year 
follow-up period. He was hereafter referred to another 
hospital due to web formation. The first girl was 11 
years old when diagnosed; she had two surgical proced-
ures performed during 23 years of follow-up. The sec-
ond girl was diagnosed at 12 years of age and under-
went 32 surgeries during a nine-year period. The third 
girl was diagnosed at eight years of age and had two sur-
gical procedures performed during a two-year follow-up 
period.
No serious complications were registered in pa-
tients treated for AORRP or JORRP; except from voice  
alterations, the most common side-effects of surgery 
were scar tissue and web formation in the anterior com-
missure of the larynx. Laryngeal stenosis did not occur. 
None of the children have received HPV vaccination.
DISCUSSION
In this long-term follow-up study of children and adults 
with RRP, we found a mean age of onset of AORPP of 45 
years and JORRP of 8.5 years, which is a slightly later 
than reported in a Danish cohort of CO2-treated RRP pa-
tients [13]. A male predominance has previously been 
reported by others [1, 13, 14]. During a mean 8.7 years 
of follow-up in the AORRP population, patients under-
went a median of four procedures, which concurs with 
previous findings [13]. In three (10%) of 30 patients for 
whom histopathology reports were available, the papil-
lomas underwent malignant transformation over time.  
A significant correlation between follow-up time and 
number of surgical procedures was shown (Figure 2). 
This is consistent with previous studies [6, 15]. However, 
significant differences in follow-up time and number of 
procedures were observed between the two groups of 
our study. In Figure 1, the surgical approach was pre-
sented as a function of time and probability of recur-
rence. Unlike previous studies, no significant difference 
between the two modalities was noted [16]. However, 
the number of surgical procedures with the microde-
brider was limited and this indicates a potentially low 
sample-size bias. 
The JORRP population consisted of four children/
adolescents. The range in number of surgical procedures 
was large (2-32). Chadha et al found a median onset of 
disease age of 3.8 years [17]. Karatayli-Ozgursoy et al 
also found a much lower age of onset in their population 
[6]. The incidence of surgeries in JORRP patients in the 
two studies was higher than in our study; probably due 
to a lower age of onset.
In the present study, no adjuvant therapy was used, 
but cidofovir injected at 2-4 week intervals has been 
proven efficient [18, 19]. Other adjuvant therapies 
(mumps vaccine, interferon, other antiviral agents, cis-
retinoic acid and more) have been employed with vari-
able success, but none have proven universally applica-
ble for RRP [9]. Future therapies like a recombinant 
fusion protein of Mycobacterium bovis heat shock pro-
tein 65 and E7 protein from HPV-16 and photodynamic 
therapy have shown promising results [9]. 
The potential effects of HPV vaccines may be di-
vided into two types. One type would be the effect of 
routine vaccination and the other would be vaccination 
after the RRP diagnosis. The implementation of HPV vac-
cines worldwide could decrease the incidence of RRP.  
In Denmark, HPV typing is now standard in RRP patients, 
and this may influence decision-making on HPV vaccin-
ation in the affected children. Until 2015, the vaccine 
was the quadrivalent Gardasil (subtypes 6, 11, 16, 18), 
but it has been changed to the bivalent Cervarix (16, 18). 
Boys are not offered this vaccination in Denmark.  
Surgical removal, preferably using narrow-band im-
aging, is still the gold standard for all RRP patients [20]. 
The most common complications to RRP surgery include 
hoarseness, synechias, stenosis and scarring due to re-
current surgery. In our material, there has been a shift 
from CO2-laser treatment to microdebrider/shaver treat-
ment. We were unable to draw any firm conclusions 
based on this shift since the latter modality was only re-
cently introduced in our department. However, it is the 
perception of the surgeons that usage of the microde-
brider is easy and causes less scar tissue. Furthermore, 
with the microdebrider it is easier to see when healthy 
tissue is reached, since it does not burn the tissue like 
the laser. Also, the microdebrider can more easily re-
FIGURE 2
Correlation between number of surgical procedures and years of follow-
up. The longer a patient has suffered from recurrent respiratory papil-
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move papillomas on the inferior part of the vocal cords, 
unlike the laser where the beam needs bending using a 
mirror, or the surgeon must apply much traction to the 
tissue to reach the necessary position [9]. Other studies 
have also documented fewer recurrences and sequelae 
in patients treated with microdebrider [9, 13, 16]. Ran-
domized controlled trials are lacking.  
Prior studies have shown a decreased QoL in both 
JORRP and AORRP patients equal to that encountered in 
other severe diseases such as cystic fibrosis and depres-
sion [3, 6, 17]. Close observation of both young and 
adult RRP patients is advised in order to manage their 
physical disease and to assess the psychological aspects 
of RRP. Guidelines concerning follow-up time and time 
intervals between visits in relapse-free patients are 
missing.  
Establishment of nationwide or international data-
bases for RRP patients could increase the knowledge 
base, create a basis for quality assessment between 
treatments and between departments and stimulate 
unification of the treatment offered to RRP patients. 
CONCLUSIONS
Young and middle-aged men were most prevalent in the 
cohort. Left-sided papillomatosis involving the vocal 
cords was most common. Most patients need multiple 
surgical procedures over time due to recurrent disease. 
HPV typing in all RRP patients is of interest for future de-
cision-making on adjuvant therapy, i.e. HPV vaccination. 
We suggest creation of a nationwide database to in-
crease evidence-based research.
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